Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence

There are no seroprevalence terms in the subcorpus

    displaying 1 - 3 records in total 3
    records per page




    Network reinforcement driven drug repurposing for COVID-19 by exploiting disease MESHD-gene-drug associations

    Authors: Yonghyun Nam; Jae-Seung Yun; Seung Mi Lee; Ji Won Park; Ziqi Chen; Brian Lee; Anurag Verma; Xia Ning; Li Shen; Dokyoon Kim

    id:2008.05377v1 Date: 2020-08-12 Source: arXiv

    Currently, the number of patients with COVID-19 has significantly increased. Thus, there is an urgent need for developing treatments for COVID-19. Drug repurposing, which is the process of reusing already-approved drugs for new medical conditions, can be a good way to solve this problem quickly and broadly. Many clinical trials for COVID-19 patients using treatments for other diseases MESHD have already been in place or will be performed at clinical sites in the near future. Additionally, patients with comorbidities such as diabetes mellitus MESHD diabetes mellitus HP, obesity MESHD obesity HP, liver cirrhosis MESHD cirrhosis HP, kidney diseases MESHD, hypertension MESHD hypertension HP, and asthma MESHD asthma HP are at higher risk for severe illness from COVID-19. Thus, the relationship of comorbidity disease MESHD with COVID-19 may help to find repurposable drugs. To reduce trial and error in finding treatments for COVID-19, we propose building a network-based drug repurposing framework to prioritize repurposable drugs. First, we utilized knowledge of COVID-19 to construct a disease MESHD-gene-drug network (DGDr-Net) representing a COVID-19-centric interactome with components for diseases MESHD, genes, and drugs. DGDr-Net consisted of 592 diseases MESHD, 26,681 human genes and 2,173 drugs, and medical information for 18 common comorbidities. The DGDr-Net recommended candidate repurposable drugs for COVID-19 through network reinforcement driven scoring algorithms. The scoring algorithms determined the priority of recommendations by utilizing graph-based semi-supervised learning. From the predicted scores, we recommended 30 drugs, including dexamethasone, resveratrol, methotrexate, indomethacin, quercetin, etc., as repurposable drugs for COVID-19, and the results were verified with drugs that have been under clinical trials. The list of drugs via a data-driven computational approach could help reduce trial-and-error in finding treatment for COVID-19.

    Continuing Our Work: Transplant Surgery And Surgical Oncology In A Tertiary Referral COVID-19 Center

    Authors: Giammauro Berardi; Marco Colasanti; Giovanni Battista Levi Sandri; Celeste Del Basso; Stefano Ferretti; Andrea Laurenzi; Nicola Guglielmo; Roberto Luca Meniconi; Mario Antonini; Gianpiero D’Offizi; Giuseppe Maria Ettorre

    doi:10.21203/rs.3.rs-27236/v1 Date: 2020-05-06 Source: ResearchSquare

    Background. COVID-19 is rapidly spreading worldwide. Healthcare systems are struggling to properly allocate resources while ensuring cure for diseases MESHD outside of the infection MESHD. The aim of this study was to demonstrate how surgical activity was affected by the virus outbreak and show the changes in practice in a tertiary referral COVID-19 center.Methods. The official bulletins of the Italian National Institute for the Infectious Diseases MESHD “L. Spallanzani” were reviewed to retrieve the number of daily COVID-19 patients. Records of consecutive oncological and transplant procedures performed during the outbreak were reviewed. Patients with a high probability of postoperative intensive care unit (ICU) admission were considered as high-risk and defined by an ASA score ≥ III and/or a Charlson Comorbidity Index (CCI) ≥ 6 and/or a Revised Cardiac Risk Index for Preoperative Risk (RCRI) ≥ 3.Results. 72 patients were operated including 12 (16.6%) liver (n=6) and kidney (n=6) transplantations. Patients had few comorbidities (26.3%), low ASA score (1.9±0.5), CCI (3.7±1.3) and RCRI (1.2±0.6) and had low risk of postoperative ICU admission. Few patients had liver cirrhosis MESHD cirrhosis HP (12.5%) or received preoperative systemic therapy (16.6%). 36 (50%) high risk surgical procedures were performed including major hepatectomies, pancreaticoduodenectomies, total gastrectomies, multivisceral resections and transplantations. Despite this, only 15 patients (20.8%) were admitted to the ICU.Conclusions. Only oncologic cases and transplantations were performed during the COVID-19 outbreak. Careful selection of patients allowed to perform major cancer surgeries and transplantations without further stressing hospital resources, meanwhile minimizing collateral damage to patients.

    Clinical Characteristics Hospitalized Patients with SARS-Cov-2 and HBV Co- infection MESHD

    Authors: Xiaoping Chen; Qunqun Jiang; Zhiyong Ma; Jiaxin Ling; Wenjia Hu; Qian Cao; Pingzheng Mo; Rongrong Yang; Shicheng Gao; Xien Gui; Yong Xiong; Jinlin Li; Yongxi Zhang

    doi:10.1101/2020.03.23.20040733 Date: 2020-03-27 Source: medRxiv

    Background & Aims The coronavirus disease MESHD 2019 (COIVD-19) caused by SARS-CoV-2 has been characterized as a pandemic, which causes a serious public health challenge in the world. A very large group of patients infected by HBV has been reported worldwide, especially in China. In order to answer whether specific treatment strategy on the patients coinfected with HBV and SARS-CoV-2, it requires profound understanding of the clinical characteristics on those patients. However, the impacts of SARS-CoV-2 infection MESHD on HBV patients remain largely unknown. Approach & Results In this retrospective investigation, we included 123 COVID-19 patients admitted to Zhongnan Hospital of Wuhan University, Wuhan, China, from January 5 to March 7, 2020. All enrolled patients are the laboratory confirmed COVID-19 pneumonia MESHD pneumonia HP cases according to the criteria reported previously. A total of 123 patients were analyzed for their Clinical records, laboratory results including the diagnosis of HBV infection MESHD and liver function. Among 123 confirmed COVID-19 patients, the mean age TRANS was 51 years old and 59.3% were females TRANS (73/123). Fifteen were previously HBV infected patients, 66.7% of them were males TRANS (10/15), patients with HBV infection MESHD appeared to have a higher incidence of liver cirrhosis MESHD cirrhosis HP and an increased level of total bilirubin. Seven (46.7%) patients with HBV infection MESHD were defined as severe cases, while the severity rate was 24.1% for the patients without HBV infection MESHD (26/108). The mortality of patients with HBV infection MESHD was 13.3% (2/15) compared to 2.8% (3/108) for the patients without HBV infection MESHD. Conclusions SARS-CoV-2 infection MESHD may cause liver function damage in COVID-19 cases and the patients with HBV infection MESHD are likely to have more severe disease MESHD outcome.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.